Adynxx, Inc. (ADYX)
Adynxx, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Francisco, CA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $581. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -379.8%. Its beta of -8.54 implies it has historically moved less than the broad market.
Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical development for reducing post-surgical discomfort. Additionally, AYX2 is a pre-clinical candidate being explored for its potential in treating localized chronic pain. Established in 2007, the company's corporate headquarters are situated in San Francisco, California.
Adynxx, Inc. is most often compared with the following Healthcare names: